Companies › Eikon Therapeutics
4 active drug programs in 6 registered trials: 3 Phase 2, 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EIK1001 Toll-like receptor 7/8 (TLR 7/8) agonist | TLR7, TLR8 | Phase 2 | NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamous or Non Squamous) | Dec 2026 |
| IMP1734 PARP1 selective inhibitor | PARP1 | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| EIK1004 (IMP1707) PARP1 selective inhibitor | PARP1 | Phase 1 | Advanced Solid Tumors | Dec 2028 |
| EIK1005 Werner helicase inhibitor | WRN | Phase 1 | Advanced Solid Tumors | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06246110 | EIK1001 | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT06253130 | IMP1734 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2027 |
| NCT06907043 | EIK1004 (IMP1707) | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2028 |
| NCT07262619 | EIK1005 | Phase 1 | Advanced Solid Tumors | Oncology | Mar 2029 |
| NCT06697301 | EIK1001 | Phase 2 | Advanced Melanoma | Oncology | Dec 2035 |
| NCT07365319 | EIK1001 | Phase 2 | Non Small Cell Lung Cancer (Squamous or Non Squamous) | Oncology | Dec 2035 |
Cash and short-term investments of $531m on 2026-06-30; operating cash outflow about $314m a year; runway about 20 months at that burn, to Mar 2028; 1 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
ALX Oncology Kura Oncology Vividion Therapeutics Cellectar Biosciences Acrivon Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.